Colgate’s Third-Century Plan positions it uniquely between research giants and liberal arts peers, by using strategic investments in research and signature programs ...

Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.

Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends ...

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative ...

Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). The collaboration will integrate ...

SIPING ROAD, YANGPU DISTRICT, SHANGHAI, CHINA, January 21, 2026 /EINPresswire.com/ -- In 2026, the global fatty acid ...

DES MOINES, IA, UNITED STATES, February 16, 2026 / EINPresswire.com / — Kelpak, the flagship liquid seaweed concentrate, was established in 1978 with a simple idea that still guides the company today.

Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for ...

Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative ...

BostonGene and Daiichi Sankyo are collaborating to integrate AI-driven translational intelligence into an antibody-drug ...